Literature DB >> 27122660

Nonalcoholic fatty liver disease as a multi-systemic disease.

Hakan Fotbolcu1, Elçin Zorlu1.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease. NAFLD includes a wide spectrum of liver conditions ranging from simple steatosis to nonalcoholic steatohepatitis and advanced hepatic fibrosis. NAFLD has been recognized as a hepatic manifestation of metabolic syndrome linked with insulin resistance. NAFLD should be considered not only a liver specific disease but also an early mediator of systemic diseases. Therefore, NAFLD is usually associated with cardiovascular disease, chronic kidney disease, type 2 diabetes, obesity, and dyslipidemia. NAFLD is highly prevalent in the general population and is associated with increased cardiovascular morbidity and mortality. The underlying mechanisms and pathogenesis of NAFLD with regard to other medical disorders are not yet fully understood. This review focuses on pathogenesis of NAFLD and its relation with other systemic diseases.

Entities:  

Keywords:  Cardiovascular effect; Insulin resistance; Multi-systemic disease; Nonalcoholic fatty liver disease; Obesity

Mesh:

Year:  2016        PMID: 27122660      PMCID: PMC4837427          DOI: 10.3748/wjg.v22.i16.4079

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  144 in total

1.  Obesity cardiomyopathy: is it a reality? An ultrasonic tissue characterization study.

Authors:  Vitantonio Di Bello; Ferruccio Santini; Andrea Di Cori; Andrea Pucci; Caterina Palagi; Maria Grazia Delle Donne; Paola Fierabracci; Alessandro Marsili; Enrica Talini; Monica Giannetti; Ombretta Biadi; Alberto Balbarini; Mario Mariani; Aldo Pinchera
Journal:  J Am Soc Echocardiogr       Date:  2006-08       Impact factor: 5.251

2.  Increased arterial stiffness in nonalcoholic fatty liver disease: the Cardio-GOOSE study.

Authors:  Paolo Salvi; Raffaele Ruffini; Davide Agnoletti; Elena Magnani; Gabriele Pagliarani; Giulia Comandini; Antonino Praticò; Claudio Borghi; Athanase Benetos; Paolo Pazzi
Journal:  J Hypertens       Date:  2010-08       Impact factor: 4.844

3.  Recommendations for probiotic use-2011 update.

Authors:  Martin H Floch; W Allan Walker; Karen Madsen; Mary Ellen Sanders; George T Macfarlane; Harry J Flint; Levinus A Dieleman; Yehuda Ringel; Stefano Guandalini; Ciaran P Kelly; Lawrence J Brandt
Journal:  J Clin Gastroenterol       Date:  2011-11       Impact factor: 3.062

4.  High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor.

Authors:  A M Thögersen; J H Jansson; K Boman; T K Nilsson; L Weinehall; F Huhtasaari; G Hallmans
Journal:  Circulation       Date:  1998-11-24       Impact factor: 29.690

5.  Beyond insulin resistance in NASH: TNF-alpha or adiponectin?

Authors:  Jason M Hui; Alex Hodge; Geoffrey C Farrell; James G Kench; Adamandia Kriketos; Jacob George
Journal:  Hepatology       Date:  2004-07       Impact factor: 17.425

Review 6.  The role of fatty acids in the development and progression of nonalcoholic fatty liver disease.

Authors:  Christopher L Gentile; Michael J Pagliassotti
Journal:  J Nutr Biochem       Date:  2008-04-21       Impact factor: 6.048

7.  Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression.

Authors:  Philip A Kern; Gina B Di Gregorio; Tong Lu; Negah Rassouli; Gouri Ranganathan
Journal:  Diabetes       Date:  2003-07       Impact factor: 9.461

8.  Metabolic syndrome and left ventricular hypertrophy in a general population. Results from the Gubbio Study.

Authors:  L A Ferrara; O Cardoni; M Mancini; A Zanchetti
Journal:  J Hum Hypertens       Date:  2007-05-17       Impact factor: 3.012

Review 9.  Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis.

Authors:  Giovanni Musso; Roberto Gambino; James H Tabibian; Mattias Ekstedt; Stergios Kechagias; Masahide Hamaguchi; Rolf Hultcrantz; Hannes Hagström; Seung Kew Yoon; Phunchai Charatcharoenwitthaya; Jacob George; Francisco Barrera; Svanhildur Hafliðadóttir; Einar Stefan Björnsson; Matthew J Armstrong; Laurence J Hopkins; Xin Gao; Sven Francque; An Verrijken; Yusuf Yilmaz; Keith D Lindor; Michael Charlton; Robin Haring; Markus M Lerch; Rainer Rettig; Henry Völzke; Seungho Ryu; Guolin Li; Linda L Wong; Mariana Machado; Helena Cortez-Pinto; Kohichiroh Yasui; Maurizio Cassader
Journal:  PLoS Med       Date:  2014-07-22       Impact factor: 11.069

Review 10.  Diacylglycerol activation of protein kinase Cε and hepatic insulin resistance.

Authors:  François R Jornayvaz; Gerald I Shulman
Journal:  Cell Metab       Date:  2012-05-02       Impact factor: 27.287

View more
  35 in total

1.  Morphofunctional Changes After Sleeve Gastrectomy and Very Low Calorie Diet in an Animal Model of Non-Alcoholic Fatty Liver Disease.

Authors:  Eider Talavera-Urquijo; Sarai Rodríguez-Navarro; Marc Beisani; Maria Teresa Salcedo-Allende; Aisha Chakkur; Marc Arús-Avilés; Manel Cremades; Salvador Augustin; María Martell; José M Balibrea
Journal:  Obes Surg       Date:  2018-01       Impact factor: 4.129

2.  Non-alcoholic fatty liver disease: a pandemic disease with multisystem burden.

Authors:  Somaya Albhaisi; Danny Issa; Naim Alkhouri
Journal:  Hepatobiliary Surg Nutr       Date:  2018-10       Impact factor: 7.293

3.  Nonalcoholic Fatty Liver Disease Is Associated with Increased Risk of Reflux Esophagitis.

Authors:  Hyo-Joon Yang; Yoosoo Chang; Soo-Kyung Park; Yoon Suk Jung; Jung Ho Park; Dong Il Park; Yong Kyun Cho; Seungho Ryu; Chong Il Sohn
Journal:  Dig Dis Sci       Date:  2017-10-23       Impact factor: 3.199

4.  Prevention of hepatic fibrosis with liver microsomal triglyceride transfer protein deletion in liver fatty acid binding protein null mice.

Authors:  Elizabeth P Newberry; Yan Xie; Susan M Kennedy; Mark J Graham; Rosanne M Crooke; Hui Jiang; Anping Chen; Daniel S Ory; Nicholas O Davidson
Journal:  Hepatology       Date:  2017-01-19       Impact factor: 17.425

5.  Nonalcoholic Fatty Liver in Lean Individuals: Clinicobiochemical Correlates of Histopathology in 157 Liver Biopsies from Healthy Liver Donors.

Authors:  Narendra S Choudhary; Neeraj Saraf; Sanjiv Saigal; Ajay Duseja; Dheeraj Gautam; Amit Rastogi; Prashant Bhangui; Srinivasan Thiagrajan; Arvinder S Soin
Journal:  J Clin Exp Hepatol       Date:  2021-02-02

Review 6.  Vitamin A signaling and homeostasis in obesity, diabetes, and metabolic disorders.

Authors:  William S Blaner
Journal:  Pharmacol Ther       Date:  2019-01-29       Impact factor: 12.310

Review 7.  Metabolic aspects of adult patients with nonalcoholic fatty liver disease.

Authors:  Ludovico Abenavoli; Natasa Milic; Laura Di Renzo; Tomislav Preveden; Milica Medić-Stojanoska; Antonino De Lorenzo
Journal:  World J Gastroenterol       Date:  2016-08-21       Impact factor: 5.742

8.  Mitochondrial dysfunction-related lipid changes occur in nonalcoholic fatty liver disease progression.

Authors:  Kang-Yu Peng; Matthew J Watt; Sander Rensen; Jan Willem Greve; Kevin Huynh; Kaushala S Jayawardana; Peter J Meikle; Ruth C R Meex
Journal:  J Lipid Res       Date:  2018-07-24       Impact factor: 5.922

9.  The association of non-alcoholic fatty liver disease and cardiac structure and function-Framingham Heart Study.

Authors:  Laura S Chiu; Alison Pedley; Joseph M Massaro; Emelia J Benjamin; Gary F Mitchell; David D McManus; Jayashri Aragam; Ramachandran S Vasan; Susan Cheng; Michelle T Long
Journal:  Liver Int       Date:  2020-07-25       Impact factor: 5.828

Review 10.  Computed Tomography Techniques, Protocols, Advancements, and Future Directions in Liver Diseases.

Authors:  Naveen M Kulkarni; Alice Fung; Avinash R Kambadakone; Benjamin M Yeh
Journal:  Magn Reson Imaging Clin N Am       Date:  2021-08       Impact factor: 1.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.